IL1B and endothelial dysfunction: TMAO hinders mitochondrial function and energy metabolism by reducing the pyruvate and fatty acid oxidation and activates the release of IL-1β and IL-18 in endothelial cells, thereby promoting endothelial dysfunction which could in turn degrade the intestinal epithelial barrier [75].